Results 121 to 130 of about 337,411 (342)

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch, Wendy Weis, Felix Huth, Seshulatha Jamalapuram, Michelle Quinlan, Amarnath Bandaru, Suleyman Eralp Bellibas, Asmae Mirkou, Shruti Kapoor, Shefali Kakar   +9 more
wiley   +1 more source

Clinical phenotypes and constipation severity in Parkinson’s disease: Relation to Prevotella species [PDF]

, 2022
Jaidaa Mekky, Shwikar Ahmad, Mona Metwali, Samar Farouk, Shehab Monir, A‎. ‎M‎. ‎A‎. El-Sayed, Sara Asser   +6 more
openalex   +1 more source

A Phase 1, Randomized, Placebo‐Controlled, Multiple‐Dose, Double‐Blind Study to Evaluate and Compare the Pharmacokinetics and Safety of Rimegepant in Healthy Adult Japanese and Caucasian Individuals

Clinical Pharmacology in Drug Development, EarlyView.
Abstract This Phase 1, randomized, placebo‐controlled, double‐blind study assessed the pharmacokinetic profile of rimegepant (25, 75, or 150 mg once daily for 14 days) in healthy Japanese and Caucasian adults. Exposures were modestly increased in Japanese participants compared with Caucasian participants following a single dose of rimegepant (Day 1 ...
Rajinder Bhardwaj, Chay Ngee Lim, Yinhua Li, Kyle T. Matschke, Richard Bertz, Robert Croop, Jing Liu   +6 more
wiley   +1 more source

Drug‐Induced QT Prolongation: Associations Between Risk Classifications in a Swedish Clinical Decision Support System and Clinical Outcomes

Clinical Pharmacology &Therapeutics, EarlyView.
Potential adverse drug events can be signaled in Clinical Decision Support Systems (CDSSs). This study validated a Swedish CDSS (Janusmed Risk Profile) by investigating associations between calculated risk classifications of drugs with QT‐prolonging potential and registered related clinical outcomes.
Ola Nordqvist, Olof Björneld, Patrick Bergman, Björn Wettermark, Alisa Lincke, Marine L. Andersson, Tora Hammar   +6 more
wiley   +1 more source

Association between constipation and incident chronic kidney disease in the UK Biobank study

Scientific Reports
Despite previous studies supporting a close relationship between constipation and chronic kidney disease (CKD), the potential impact of constipation on incident CKD and the role of laxatives remains uncertain.
Kipyo Kim, Won-Hee Cho, Seun Deuk Hwang, Seoung Woo Lee, Joon Ho Song   +4 more
doaj   +1 more source

On the Treatment of Habitual Constipation in Infants [PDF]

, 1888
E. O’Brian Smith
openalex   +1 more source

The Prevalence and Burden of Avoidant/Restrictive Food Intake Disorder (ARFID) Symptoms in the Adult General Population of the UK and USA

International Journal of Eating Disorders, EarlyView.
ABSTRACT Introduction Avoidant/Restrictive Food Intake Disorder (ARFID) is a feeding and eating disorder characterized by avoidant/restrictive eating behaviors that lead to medical and/or functional impairments. While ARFID is increasingly recognized within pediatric populations and specialist clinics, data on its prevalence and burden within the adult
Grace Brownlow, Rosie Flack, Helen Burton‐Murray, Olafur Palsson, Imran Aziz   +4 more
wiley   +1 more source

A retrospective study of the efficacy and safety of naldemedine for opioid‐induced constipation in thoracic cancer patients

, 2022
Hisao Imai, Yukiyoshi Fujita, Eriko Hiruta, Takashi Masuno, Shigeki Yamazaki, Hajime Tanaka, Teruhiko Kamiya, Mitsuru Sandoh, Satoshi Takei, Kazuya Arai, Hiromi Nishiba, Junnosuke Mogi, Kyoichi Kaira, Koichi Minato   +13 more
openalex   +1 more source

Prevalence and determinants of constipation in children in Asia: a systematic review and meta-analysisResearch in context

EClinicalMedicine
Summary: Background: Constipation is prevalent worldwide, significantly increasing healthcare costs and diminishing the quality of life in children affected.
Felicia Djurijanto, Shyh-Hsiang Lin, Nguyen-Phong Vo, Nguyen Quoc Khanh Le, Anh Nguyen-Hoang, Szu-Chuan Shen, Chung-Hsin Wu, Jian-Yu Chen, Ngan Thi Kim Nguyen   +8 more
doaj   +1 more source

Pharmacological treatment for patients with obesity and heart failure: Focus on glucagon‐like peptide‐1 receptor agonists. European Journal of Heart Failure expert consensus document

European Journal of Heart Failure, EarlyView.
There is growing clinical interest in strategies for improving clinical outcomes in patients with heart failure (HF) and obesity. The development of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and of the dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 RA has expanded therapeutic options for this population. This expert consensus
Luca Monzo, Gianluigi Savarese, Wilfried Mullens, Amr Abdin, Biykem Bozkurt, Ovidiu Chioncel, Seif El Hadidi, Thomas M. Gorter, Riccardo M. Inciardi, Mark C. Petrie, Gabriele G. Schiattarella, Davide Stolfo, Marco Metra, Nicolas Girerd   +13 more
wiley   +1 more source